Please login to the form below

Not currently logged in
Email:
Password:

CoStim Pharmaceuticals

This page shows the latest CoStim Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

Novartis enters PD-1 race via CoStim acquisition

Novartis enters PD-1 race via CoStim acquisition

Expands presence in cancer immunotherapies. Novartis has reached a deal to acquire US company CoStim Pharmaceuticals, expanding its position in the hot topic of cancer immunotherapy. ... Boston, Massachusetts-based CoStim - which started operations in

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics